GlassScriptPhysician profile
Natalie Pachinger
NPI 1427687029
$11,127.42
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,254 · 2022: $4,178 · 2023: $2,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,695.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,547.53 | 2021-2023 | Enbrel, Tavneos, Prolia |
| Abbvie INC. | $1,534.97 | 2021-2023 | |
| Horizon Therapeutics Plc | $832.30 | 2021-2023 | Krystexxa |
| Ucb, INC. | $757.77 | 2021-2023 | Cimzia |
| Lilly USA, LLC | $611.62 | 2021-2023 | Olumiant, Taltz |
| Mallinckrodt Hospital Products INC. | $561.32 | 2021-2023 | Acthar |
| Alexion Pharmaceuticals, INC. | $538.78 | 2021-2023 | Strensiq |
| Glaxosmithkline, LLC. | $515.85 | 2021-2023 | Benlysta |
| Pfizer INC. | $492.86 | 2021-2023 | |
| Genentech USA, INC. | $415.59 | 2021-2023 | Actemra, Rituxan |
| Janssen Biotech, INC. | $401.07 | 2021-2023 | Tremfya |
| Aurinia Pharma U.S., INC. | $358.80 | 2021-2023 | Lupkynis |
| Ani Pharmaceuticals, INC. | $333.38 | 2022-2023 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $297.77 | 2021-2023 | Orencia |
| Novartis Pharmaceuticals Corporation | $294.33 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $272.47 | 2022-2023 | Octagam Immune Globulin (Human) |
| Arbor Pharmaceuticals, INC. | $214.04 | 2021-2022 | |
| Radius Health, INC. | $200.65 | 2021-2023 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $181.45 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.52 | 2021-2023 | |
| Organon LLC | $156.29 | 2021-2023 | Renflexis, Hadlima |
| Antares Pharma, INC. | $75.66 | 2021 | |
| Sobi, INC | $68.03 | 2021-2022 | |
| Eisai INC. | $55.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.82 | 2023 | Hyqvia |
| Kiniksa Pharmaceuticals, LTD. | $42.62 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $35.01 | 2021 | |
| Bioventus LLC | $33.43 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $27.43 | 2023 | Iovera, Zilretta |
| Almatica Pharma LLC | $23.55 | 2022 | |
| Fresenius Kabi USA, LLC | $15.77 | 2023 | Idacio |
| Fidia Pharma USA INC. | $13.16 | 2023 | Hymovis, Triluron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Pachinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.